Janssen Presented Results of RSV Vaccine in P-IIb CYPRESS Study for Lower Respiratory Tract Disease Due to Respiratory Syncytial Virus at IDWeek 2021
Shots: The P-IIb CYPRESS study evaluates the efficacy & safety of RSV vaccine vs PBO in a ratio (1:1) in 5782 patients aged ≥65 with LRTD caused by RSV The study met its 1EPs & 2EPs i.e., 80% efficacy against RSV-associated LRTD & 70% against any symptomatic RSV-associated ARI. The vaccine showed robust humoral & […]